626 related articles for article (PubMed ID: 30631324)
21. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
22. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
23. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
24. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
26. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
[TBL] [Abstract][Full Text] [Related]
27. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice.
Cong H; Mui EJ; Witola WH; Sidney J; Alexander J; Sette A; Maewal A; El Bissati K; Zhou Y; Suzuki Y; Lee D; Woods S; Sommerville C; Henriquez FL; Roberts CW; McLeod R
Hum Immunol; 2012 Jan; 73(1):1-10. PubMed ID: 22027386
[TBL] [Abstract][Full Text] [Related]
28. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
30. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
31. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
32. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
33. Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model.
Liu TY; Giddam AK; Hussein WM; Jia Z; McMillan NA; Monteiro MJ; Toth I; Skwarczynski M
Curr Drug Deliv; 2015; 12(1):3-8. PubMed ID: 25269453
[TBL] [Abstract][Full Text] [Related]
34. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
35. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
36. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
37. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
38. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers.
Xiang SD; Wilson K; Day S; Fuchsberger M; Plebanski M
Methods; 2013 May; 60(3):232-41. PubMed ID: 23643867
[TBL] [Abstract][Full Text] [Related]
39. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]